Cargando…
Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results
PURPOSE: Eribulin mesilate was approved for the treatment of patients with locally advanced or metastatic breast cancer (MBC), who had received at least two chemotherapeutic regimens, including anthracycline and taxane. On the other hand, the efficacy and safety information of eribulin in Korean pat...
Autores principales: | Park, Yeon Hee, Kim, Tae Yong, Im, Young-Hyuck, Lee, Keun-Seok, Park, In Hae, Sohn, Joohyuk, Lee, Soo-Hyeon, Im, Seock-Ah, Kim, Jee Hyun, Kim, Se Hyun, Lee, Soo Jung, Koh, Su-Jin, Lee, Ki Hyeong, Choi, Yoon Ji, Cho, Eun Kyung, Lee, Suee, Kang, Seok Yun, Seo, Jae Hong, Kim, Sung-Bae, Jung, Kyung Hae |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Cancer Association
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5398406/ https://www.ncbi.nlm.nih.gov/pubmed/27488876 http://dx.doi.org/10.4143/crt.2016.191 |
Ejemplares similares
-
Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11)
por: Kim, Ji-Yeon, et al.
Publicado: (2019) -
Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2 + metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16)
por: Sim, Sung Hoon, et al.
Publicado: (2019) -
A nationwide, multicenter retrospective study on the effectiveness and safety of eribulin in Korean breast cancer patients (REMARK)
por: Park, Min Ho, et al.
Publicado: (2020) -
2018 Korean Clinical Imaging Guideline for Hemoptysis
por: Kang, Mi-Jin, et al.
Publicado: (2018) -
Cardiac arrest caused by nafamostat mesilate
por: Kim, Hyo Shik, et al.
Publicado: (2016)